A New Prognostic Score for Survival of Patients With Chronic Myeloid Leukemia Treated With Interferon Alfa Writing Committee for the Collaborative CML Prognostic Factors Project GroupJoerg Hasford, Hassan Ansari, Markus Pfirrmann et al.|JNCI Journal of the National Cancer Institute|1998Cited by 820
Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS scoreJoerg Hasford, Rüdiger Hehlmann, Michele Baccarani et al.|Blood|2011Cited by 497
Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. The German CML Study Group [see comments]Rüdiger Hehlmann, B Heinze, H. Heimpel et al.|Blood|1994Cited by 458
Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML)Benjamin Hanfstein, Marc Müller, Rüdiger Hehlmann et al.|Leukemia|2012Cited by 417
Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinantsRoland J. Fuchs, Rüdiger Hehlmann, Michael Lauseker et al.|Leukemia|2017Cited by 339